On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) to expand the conditional marketing authorization (CMA) of Nuvaxovidﾙ (NVX-CoV2373) COVID-19 vaccine? as a homologous and heterologous booster dose for individuals aged 18 and over.

This request for expanded CMA is supported by data from Novavax’ Phase 2 trial conducted in Australia, from a separate Phase 2 trial conducted in South Africa, and from the UK-sponsored COV-BOOST trial.